Status:
COMPLETED
Telmisartan for Treatment of COVID-19 Patients
Lead Sponsor:
Laboratorio Elea Phoenix S.A.
Collaborating Sponsors:
Carlos R. Rojo, MD
Facultad de Medicina, Universidad de Buenos Aires, UBA
Conditions:
COVID-19 Drug Treatment
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002-2003 epidemic. This new disease was named COV...
Detailed Description
In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus (SARS-CoV) in the 2002-2003 epidemic. This new disease wa...
Eligibility Criteria
Inclusion
- Aged 18 years or older
- Confirmed diagnosis of COVID-19 by PCR test
- Hospitalization for COVID-19
- Illness symptoms beginning 4 days or less prior to randomization
Exclusion
- Admitted to ICU prior to randomization
- Illness symptoms beginning more than 4 days prior to randomization
- Pregnancy
- Breast feeding
- Major hypersensibility to angiotensin receptor blockers (ARBs)
- Systolic blood pressure \< 100mmHg
- Potassium greater than 5.5 mEq/L
- AST and/or ALT \> 3 times the upper limit of normal
- Serum creatinine higher than 3 mg/dL
- Current treatment with angiotensin converting enzyme inhibitor (ACEi) or ARB
Key Trial Info
Start Date :
May 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2020
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04355936
Start Date
May 19 2020
End Date
November 30 2020
Last Update
December 24 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Clínicas 'José de San Martín', Facultad de Medicina, Universidad de Buenos Aires
Buenos Aires, Buenos Aires F.D., Argentina, C1120AAR
2
Hospital Español de Buenos Aires
Buenos Aires, Argentina, 1209